COMPOZITII FARMACEUTICE PE BAZA DE PROTEINA DIN PLASMA

Price not visible for this package

Interest:

Assignment

Publication info:

No.: RO118695

Date: 30.09.2003

Inventor(s):

HEGEDUS LAJOS [HU]

KREMPELS KRISZTINA [HU]

PAAL KRISZTINA [HU]

PETHO GABOR [HU]

Applicant(s):
HUMAN RT [HU]
Classification:
International patent classification (IPC):
A61K31/05; A61K31/137; A61K31/192; A61K31/20; A61K47/42; A61K9/08; A61P35/00; A61P37/00; A61K38/00

Cooperative patent classification (CPC):
A61K31/335 (EP, US); A61K31/337 (EP, US); A61K31/5513 (EP, US); A61K38/13 (EP, US); A61K38/20 (EP, US); A61K38/21 (EP, US); A61K47/42 (EP, KR, US); A61K9/0019 (EP, US); A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP); A61K38/20; A61K2300/00; A61K38/21
Application info:
No.: RO19200000315
Date: 17.09.1998
Priority number(s):
HU19970001554 18.09.1997 ; WO1998HU00086 17.09.1998
Related patents:
AR017120; ATE230611; AU734695; AU9362398; BG104245; BG64749; BR9812469; CA2269923; CN1189216; CN1270529; CZ2000952; CZ301326; DE69810612; DK0981375; EA004700; EA200000331; EP0981375; ES2187062; HRP980499; IL135055; JP2001508806; KR100587962; KR20010052072; LT2000018; LT4736; LV12493; NO20001371; NO325294; NZ503302; PL193067; PL339369; PT981375; RS50102; SI20189; SK284683; SK3292000; TR200001545; TWI222365; US2004014655; US2005064028; US2007232536; US2010076008; US6743826; US7119124; US7501455; US8946167; WO9913914; YU16600; ZA988585
Description:

Inventia se refera la compozitii farmaceutice pe baza de proteina din plasma, la un procedeu de preparare a acestora si la o metoda de tratament. Compozitiile farmaceutice conform inventiei contin osubstanta activa terapeutic, cu solubilitate mica in apa, mare afinitate de legare la proteinele din plasma, o fractiune de proteina din plasma in stare de agregare controlata, in care substanta activa mentionata si fractiunea de proteina mentionata sunt legate una de alta prin legaturi covalente, si un aditiv sau aditivi acceptabil/i farmaceutic. Procedeul de preparare a acestora consta in aceea ca se dizolva compusul activ terapeutic intr-un solvent organic miscibil cu apa, se combina aceste solutii cu solutia apoasa a fractiunii de proteina din plasma, se combina cu inca un aditiv acceptabil farmaceutic, se indeparteaza solventul organic, eventual se dizolva produsul solid in apa si se formuleaza farmaceutic.